HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023

HOOKIPA Pharma Inc.

Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.
Q4 revenue $7.8M, full-year $14.2M (down from $18.4M); net loss $64.9M for 2022 vs $75.7M in 2021.
HB-200 Phase 2 data (with pembrolizumab) due 2Q2023; HB-300 trial open; HB-700 IND planned 1H2024.
Roche collaboration: $10M milestone Feb 2023; potential milestones up to $930M plus royalties.
Gilead HBV milestone $5M Jan 2023; HIV program IND expected 2023; HB-101 program discontinued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HOOKIPA Pharma Inc. reported financial results for Fourth Quarter and Full Year 2022.

Period: Fourth Quarter and Full Year 2022
Result: reported results

Exact text from the filing

On March 15, 2023, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2022.

View on SEC.gov

Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-003776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.